[{"orgOrder":0,"company":"Medytox","sponsor":"Bloomage Biotechnology Corp., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Termination","leadProduct":"Botulinum Toxin A","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Medytox","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medytox \/ Bloomage Biotechnology Corp., Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Medytox \/ Bloomage Biotechnology Corp., Ltd"}]

Find Clinical Drug Pipeline Developments & Deals by Medytox

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Medytox applied for a license for Meditoxin (export name: Neuronox having Clostridium Botulinum Toxin type A), Medytox’s BTX product, to China’s National Medical Products Administration in February 2018.

                          Product Name : Neuronox

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          April 08, 2022

                          Lead Product(s) : Botulinum Toxin A

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Sponsor : Bloomage Biotechnology Corp., Ltd

                          Deal Size : Undisclosed

                          Deal Type : Termination

                          blank